Boston Scientific completed the acquisition of Preventice Solutions for $1.2bn.

Boston Scientific, a global medical technology firm, completed the acquisition of Preventice Solutions, a provider of mobile cardiac health solutions and services, for $1.2bn, comprising of an upfront cash payment of $925m, and an additional $300m in a potential commercial milestone payment. "We are confident that by adding the broad technology portfolio and expertise of Preventice, our combined teams can continue to deliver rapid growth in these highly-attractive markets while also establishing an important adjacency to our core cardiac rhythm management and electrophysiology businesses," Scott Olson, Boston Scientific Senior Vice President and President of Rhythm Management.